Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CDA | P32320 | 6/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906558 | 1.00 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL25188377 | 0.88 | CDA (0.43) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL31436719 | 0.87 | CDA (0.42) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL10903345 | 0.87 | CDA (0.42) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL29845228 | 0.85 | CDA (0.41) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL4751008 | 0.85 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL17440122 | 0.85 | CDA (0.41) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL27845966 | 0.85 | CDA (0.41) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL22978939 | 0.85 | CDA (0.41) | LMNASMN1; SMN2ALDH1A1POLBCDA | |
| SCHEMBL10903331 | 0.85 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1POLBCDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110719954-B | Therapeutic agent for glycogen storage disease type III | 奥特吉尼克斯制药公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20140171635-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | SOLULINK BIOSCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8541555-B2 | Hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers | SOLULINK BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2150858-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | Solulink, INC. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008140452-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | SOLULINK, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080221343-A1 | Labeled biomolecules of chromophore or the fluorophore incorporated into the linker between a reactive linking moiety and a biotin molecule; proteins, nucleic acids | AUDAX PRIVATE DEBT LLC, AS AGENT | 2008-09-11 | — | — | US | disclosed |
| US-7402588-B2 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | EMORY UNIVERSITY (US) | 2008-07-22 | — | — | US | disclosed |
| US-20060276492-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | LIOTTA DENNIS C | 2006-12-07 | — | — | US | disclosed |
| US-4749647-A | Polymerization-induced separation assay using recognition pairs | GENETIC SYSTEMS CORPORATION (US) | 1988-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221343-A1 | Labeled biomolecules of chromophore or the fluorophore incorporated into the linker between a reactive linking moiety and a biotin molecule; proteins, nucleic acids | RRP12, MRPS22, HBG2 | LMNA 214/4885SMN1; SMN2 3674/4885ALDH1A1 3046/4885 |
| US-20060276492-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | PNP, MTAP, ENTPD5 | LMNA 2588/4885SMN1; SMN2 2807/4885ALDH1A1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.